The effect of dexmedetomidine on the prognosis of children with severe sepsis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200056383

Enrollment

Unknown

Registered

2022-02-04

Start date

2022-02-01

Completion date

Unknown

Last updated

2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric severe sepsis

Interventions

dexmedetomidine group:sedated with dexmedetomidine

control group:sedated without dexmedetomidine

Eligibility

Sex/Gender

All

Age

29 Days to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 29 days and <= 18 years; 2. Meet the diagnostic criteria of pediatric severe sepsis or septic shock; 3. Receiving mechanical ventilation.

Exclusion criteria

Exclusion criteria: 1. Allergic to dexmedetomidine; 2. Length of PICU stay <= 24 hours; 3. Refused to join the study.

Design outcomes

Primary

Measure	Time frame
in-hospital mortality;28-day mortality;	—

Secondary

Measure	Time frame
the incidence of acute kidney injury;recovery of renal function;the proportion of children requiring renal replacement therapy;the incidence of hypotension;the incidence of delirium;the cost in PICU;the changes of sub-score of pSOFA;	—

Countries

China

Contacts

Public ContactJin Youpeng

Provincial Hospital affiliated to Shandong First Medical University(Shandong Provincial Hospital)

jinyp79@sina.cn+86 15168863809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026